FR3134960B3 - Système de détection d’un risque d’abandon d’un traitement de la maladie de Parkinson - Google Patents

Système de détection d’un risque d’abandon d’un traitement de la maladie de Parkinson Download PDF

Info

Publication number
FR3134960B3
FR3134960B3 FR2204012A FR2204012A FR3134960B3 FR 3134960 B3 FR3134960 B3 FR 3134960B3 FR 2204012 A FR2204012 A FR 2204012A FR 2204012 A FR2204012 A FR 2204012A FR 3134960 B3 FR3134960 B3 FR 3134960B3
Authority
FR
France
Prior art keywords
risk
treatment
parkinson
disease
alert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2204012A
Other languages
English (en)
Other versions
FR3134960A3 (fr
Inventor
Christopher Cala
François Meunier
Habiboulaye Amadou-Boubacar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Air Liquide SA
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Original Assignee
Air Liquide SA
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Air Liquide SA, LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude filed Critical Air Liquide SA
Priority to FR2204012A priority Critical patent/FR3134960B3/fr
Publication of FR3134960A3 publication Critical patent/FR3134960A3/fr
Application granted granted Critical
Publication of FR3134960B3 publication Critical patent/FR3134960B3/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4833—Assessment of subject's compliance to treatment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • General Business, Economics & Management (AREA)
  • Pathology (AREA)
  • Business, Economics & Management (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Titre de l’invention Système de détection d’un risque d’abandon d’un traitement de la maladie de Parkinson L’invention concerne un système de détection d’un risque d’abandon d’un traitement de la maladie de Parkinson par un patient atteint de ladite maladie de Parkinson et suivant un traitement par perfusion d’apomorphine au moyen d’une pompe de perfusion. Des moyens de détermination permettent de déterminer un ou des paramètres de la pompe de perfusion, à savoir concentration en apomorphine, durée de perfusion et dose totale perfusée. Des moyens de traitement informatique à processeur permettent de traiter le ou les paramètres au moyen d’un premier modèle mathématique prédéfini pour en déduire un score de risque d’abandon du traitement par le patient. Des moyens d’alerte déclenchent une alerte de risque d’abandon du traitement lorsque le score de risque excède un seuil d’alerte donné préfixé. Des moyens d’affichage affichent notamment ce score de risque. Préférentiellement, un second modèle mathématique permet de calculer une recommandation d'action en cas d'alerte. Figure de l’abrégé : Fig. 1
FR2204012A 2022-04-28 2022-04-28 Système de détection d’un risque d’abandon d’un traitement de la maladie de Parkinson Active FR3134960B3 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR2204012A FR3134960B3 (fr) 2022-04-28 2022-04-28 Système de détection d’un risque d’abandon d’un traitement de la maladie de Parkinson

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2204012A FR3134960B3 (fr) 2022-04-28 2022-04-28 Système de détection d’un risque d’abandon d’un traitement de la maladie de Parkinson
FR2204012 2022-04-28

Publications (2)

Publication Number Publication Date
FR3134960A3 FR3134960A3 (fr) 2023-11-03
FR3134960B3 true FR3134960B3 (fr) 2024-05-03

Family

ID=88519912

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2204012A Active FR3134960B3 (fr) 2022-04-28 2022-04-28 Système de détection d’un risque d’abandon d’un traitement de la maladie de Parkinson

Country Status (1)

Country Link
FR (1) FR3134960B3 (fr)

Also Published As

Publication number Publication date
FR3134960A3 (fr) 2023-11-03

Similar Documents

Publication Publication Date Title
Fauser et al. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times
Weber et al. Repeated social defeat, neuroinflammation, and behavior: monocytes carry the signal
Moore et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults
JP7398031B2 (ja) 治療用血漿タンパク質投与計画を提供するための方法、およびマシンアクセス可能デバイス
Nutt et al. Effect of long-term therapy on the pharmacodynamics of levodopa: relation to on-off phenomenon
Jamal et al. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration
EP1930039A2 (fr) Système pour détécter des occlusions de manière rapide dans une pompe à seringue
Kee Phenylephrine infusions for maintaining blood pressure during spinal anesthesia for cesarean delivery: finding the shoe that fits
TWI672602B (zh) 提供藥物動力學藥物給藥方案的方法和設備
FR3134960B3 (fr) Système de détection d’un risque d’abandon d’un traitement de la maladie de Parkinson
Brown et al. Pharmacokinetics of intravenous N-acetylcysteine in men at rest and during exercise
DE60322084D1 (de) Vorrichtung und verfahren zur qualitativen und quantitativen bestimmung von intravenösen flüssigkeitskomponenten
Aaronson et al. Relationship between prolonged intraocular inflammation and macular edema after cataract surgery
Hua et al. Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B
FR2872708A1 (fr) Dispositif de commande d'administration de principe actif
Scherlinger et al. O5 Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014
Tamura et al. In vivo evaluation of ocular inflammatory responses in experimental diabetes
WO2015010022A2 (fr) Méthode de diagnostic et de stabilisation de symptômes de sfc/emm chez un patient candidat
Lin et al. Apraclonidine attenuates the increases in spinal excitatory amino acid release in rats with adjuvant-induced inflammation
Villgran et al. An Unusual Case of Eosinophilic Pleural Effusion and Rivaroxaban Hypersensitivity
Ekart et al. EARLY DETECTION OF THE STENOSIS IN THE HEMODIALYSIS ARTERIOVENOUS FISTULA USING ROUTINELY MEASUREMENT OF THE DIALYSIS DOSE KT/V
Beleña et al. Migraine headache: a rare complication after cervicothoracic block
Codreanu et al. FRI0119 TITLE USE OF JAK INHIBITORS IN THE TREATMENT OF RA PATIENTS IN THE ROMANIAN REGISTRY OF RHEUMATIC DISEASES
WO2022140012A1 (fr) Système de surveillance du sang pour la détection d'hémorragies occultes
Barratt et al. Atacicept in IgA Nephropathy (IgAN): Continued Protective Titers to Diphtheria and Tetanus and Balanced Infections vs. Placebo with a Focus on COVID-19: SA-PO884

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLFP Fee payment

Year of fee payment: 3